Dofort Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.80 Cr
as on 10-01-2025
- Paid Up Capital ₹ 1.24 M
as on 10-01-2025
- Company Age 18 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 315.39%
(FY 2016)
- Profit 509.36%
(FY 2016)
- Ebitda -348.62%
(FY 2016)
- Net Worth 3.62%
(FY 2016)
- Total Assets 3.91%
(FY 2016)
About Dofort Pharma
The Corporate was formerly known as Day Lewis Chemist Pvt. Ltd.. The Company is engaged in the Financial Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.80 Cr and a paid-up capital of Rs 1.24 M, as per Ministry of Corporate Affairs (MCA) records.
Jayantilal Patel, Kirit Patel, Jayanti Patel, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24232GJ2006PTC049026
- Company No.
049026
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Sep 2006
- Date of AGM
17 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Dofort Pharma?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jayantilal Patel  | Director | 02-Feb-2007 | Current |
| Kirit Patel | Director | 26-Oct-2018 | Current |
| Jayanti Patel | Director | 26-Oct-2018 | Current |
Rajan Parikh  | Director | 07-Oct-2019 | Current |
| Jayesh Parikh | Director | 01-Feb-2011 | Current |
Financial Performance of Dofort Pharma.
Dofort Pharma Private Limited, for the financial year ended 2016, experienced significant growth in revenue, with a 315.39% increase. The company also saw a substantial improvement in profitability, with a 509.36% increase in profit. The company's net worth moved up by a moderate rise of 3.62%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dofort Pharma?
In 2016, Dofort Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Megafine Speciality Chemicals Private LimitedActive 13 years 2 monthsRajan Parikh is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Dofort Pharma?
Unlock and access historical data on people associated with Dofort Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dofort Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dofort Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
